Document is current
Any future updates will be listed below
-
Authors
Liu, Jia
Lu, Yan
Bhuiyan, Piplu
Gruttner, Jacob
St. Louis, Lauren
Yi, Yutong
Liang, Ge
Wei, Huafeng https://orcid.org/0000-0003-3077-6574
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG061447)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG061447)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG061447)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG061447)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG061447)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG061447)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG061447)
NIA R01 Supplemental
- License Information
-
More Information
Article History
Received: 18 March 2025
Revised: 8 December 2025
Accepted: 20 January 2026
First Online: 3 February 2026
Competing interests
: Drs. Huafeng Wei and Ge Liang are listed as inventors of patents entitled “Intranasal Administration of Dantrolene for Treatment of Alzheimer’s Disease” in multiple countries by The Trustees of the University of Pennsylvania. Dr. Huafeng Wei is listed as the inventor of the USA patents application repurposing intranasal dantrolene nanoparticles to treat neurodegenerative diseases and psychiatric disorders.
: All methods were performed in accordance with the relevant guidelines and regulations. This study was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Pennsylvania, under approval number 805897. Informed consent was obtained from all participants prior to their inclusion in the study.
